Pharmacovigilance study of INSTIs associated with weight gain and glucose/lipid metabolism adverse events based on the FDA adverse event reporting system.

Key Points

• The research aims to identify metabolic adverse events (AEs) associated with integrase strand transfer inhibitors (INSTIs).
• Utilized the FDA adverse event reporting system for data collection.
• Analyzed agent-specific differences in risks and timing of metabolic AEs.
• Assessed trends in glucose and lipid metabolism changes during ART.
• Identified significant metabolic AEs linked to different INSTIs.
• Observed variations in risk levels and timing of occurrences for specific agents.
• Recommended ongoing monitoring and tailored management strategies for patients on INSTIs.